EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ATAI Life Sciences NV's Enterprise Value is $156.30 Mil.
ATAI Life Sciences NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-84.71 Mil. Therefore, ATAI Life Sciences NV's EV-to-FCF for today is -1.85.
The historical rank and industry rank for ATAI Life Sciences NV's EV-to-FCF or its related term are showing as below:
ATAI'
s EV-to-FCF Range Over the Past 10 Years
Min: -85.07 Med: -2.11 Max: 0.56
Current: -1.85
During the past 5 years, the highest EV-to-FCF of ATAI Life Sciences NV was 0.56. The lowest was -85.07. And the median was -2.11.
ATAI's EV-to-FCF is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 6.365
vs ATAI: -1.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ATAI Life Sciences NV's EV-to-FCF
For the Biotechnology subindustry, ATAI Life Sciences NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ATAI Life Sciences NV's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ATAI Life Sciences NV's EV-to-FCF falls into.
ATAI Life Sciences NV's current Enterprise Value is $156.30 Mil.
ATAI Life Sciences NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (NAS:ATAI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ATAI Life Sciences NV's PE Ratio for today is calculated as:
ATAI Life Sciences NV's share price for today is $1.89.
ATAI Life Sciences NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ATAI Life Sciences NV EV-to-FCF Related Terms
Thank you for viewing the detailed overview of ATAI Life Sciences NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your 